"spastizin" meaning in English

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "spastizin (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms suffixed with -in",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Proteins",
          "orig": "en:Proteins",
          "parents": [
            "Biomolecules",
            "Biochemistry",
            "Body parts",
            "Organic compounds",
            "Biology",
            "Chemistry",
            "Body",
            "Anatomy",
            "Matter",
            "Sciences",
            "All topics",
            "Medicine",
            "Nature",
            "Fundamental",
            "Healthcare",
            "Health"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2015 June 17, Jennifer Hirst et al., “Loss of AP-5 results in accumulation of aberrant endolysosomes: defining a new type of lysosomal storage disease”, in Human Molecular Genetics, volume 24, →DOI:",
          "text": "Antibodies used in this study include in-house antibodies against clathrin, AP-5 ζ (monoclonal antibody used for IF), µ5 and SPG11 monoclonal (4) and spastizin [PER antibody (49)] and commercial antibodies against spastizin (Atlas HPA035693), EEA1 (BD Transduction Labs E41120), LAMP1 (Abcam ab24170 and H4A3), CIMPR (2G11; Calbiochem 444105), AP-2 µ2 (AP50; BD Transduction Labs 611351), LC3 (4E12; MBL M152-3B), LBPA (Jean Gruenberg), CD63 (H5C6; BD Biosciences), tubulin (DM1A, Abcam ab7291) and actin (C4, Abcam ab3280).",
          "type": "quote"
        }
      ],
      "glosses": [
        "A protein, characteristic of spastic paraplegia, that mediates autophagic lysosome reformation"
      ],
      "id": "en-spastizin-en-noun-dmKfpNGE",
      "links": [
        [
          "biochemistry",
          "biochemistry"
        ],
        [
          "protein",
          "protein"
        ],
        [
          "spastic",
          "spastic"
        ],
        [
          "paraplegia",
          "paraplegia"
        ],
        [
          "autophagic",
          "autophagic"
        ],
        [
          "lysosome",
          "lysosome"
        ]
      ],
      "raw_glosses": [
        "(biochemistry) A protein, characteristic of spastic paraplegia, that mediates autophagic lysosome reformation"
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "biochemistry",
        "biology",
        "chemistry",
        "microbiology",
        "natural-sciences",
        "physical-sciences"
      ]
    }
  ],
  "word": "spastizin"
}

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "spastizin (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms suffixed with -in",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry",
        "Pages with entries",
        "en:Proteins"
      ],
      "examples": [
        {
          "ref": "2015 June 17, Jennifer Hirst et al., “Loss of AP-5 results in accumulation of aberrant endolysosomes: defining a new type of lysosomal storage disease”, in Human Molecular Genetics, volume 24, →DOI:",
          "text": "Antibodies used in this study include in-house antibodies against clathrin, AP-5 ζ (monoclonal antibody used for IF), µ5 and SPG11 monoclonal (4) and spastizin [PER antibody (49)] and commercial antibodies against spastizin (Atlas HPA035693), EEA1 (BD Transduction Labs E41120), LAMP1 (Abcam ab24170 and H4A3), CIMPR (2G11; Calbiochem 444105), AP-2 µ2 (AP50; BD Transduction Labs 611351), LC3 (4E12; MBL M152-3B), LBPA (Jean Gruenberg), CD63 (H5C6; BD Biosciences), tubulin (DM1A, Abcam ab7291) and actin (C4, Abcam ab3280).",
          "type": "quote"
        }
      ],
      "glosses": [
        "A protein, characteristic of spastic paraplegia, that mediates autophagic lysosome reformation"
      ],
      "links": [
        [
          "biochemistry",
          "biochemistry"
        ],
        [
          "protein",
          "protein"
        ],
        [
          "spastic",
          "spastic"
        ],
        [
          "paraplegia",
          "paraplegia"
        ],
        [
          "autophagic",
          "autophagic"
        ],
        [
          "lysosome",
          "lysosome"
        ]
      ],
      "raw_glosses": [
        "(biochemistry) A protein, characteristic of spastic paraplegia, that mediates autophagic lysosome reformation"
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "biochemistry",
        "biology",
        "chemistry",
        "microbiology",
        "natural-sciences",
        "physical-sciences"
      ]
    }
  ],
  "word": "spastizin"
}